|
|
Article: New Study: GRAZAX(R) Shows Significant Cost-Effectiveness.
- Article from:
- PR Newswire Europe
- Article date:
- June 11, 2007
CopyrightCOPYRIGHT 2007 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
HORSHOLM, Denmark, June 11 /PRNewswire/ -- More than seventeen million people in the United Kingdom, Germany, the Netherlands, Sweden, Denmark, Norway and Finland suffer from grass pollen induced allergic rhinitis. While symptomatic therapy has shown to be partially effective, a new tablet-based allergy vaccine GRAZAX(R) has shown to be both effective at symptom reduction and cost-effective.
New data published in Clinical & Experimental Allergy and presented at the European Academy of Allergology and Clinical Immunology (EAACI) congress today assessed the cost-effectiveness of the only grass allergen tablet on the market. The study compared GRAZAX(R) with ...